Accrued Expenses & Other Current Liabilities

12 Months Ended

Dec. 31, 2020

Payables and Accruals [Abstract]

Accrued Expenses & Other Current Liabilities

Accrued Expenses & Other Current Liabilities

Accrued expenses and other current liabilities consist of the following:

	DECEMBER 31,
(in thousands)	2020		2019
Accrued expenses and other current liabilities:
Accrued compensation and benefits	$	15,207	$	11,169
Accrued consulting and professional fees	2,645		3,810
Accrued research and development (1)	2,222		8,734
Accrued revenue reserves(2)	66,552		38,450
Accrued other(3)	4,097		3,213
Total accrued expenses and other current liabilities	$	90,723	$	65,376

(1)Comprised primarily of accruals related to fees for investigative sites, contract research organizations and other service providers that assist in conducting preclinical research studies and clinical trials. As of December 31, 2019, liabilities incurred related to the Avizorex acquisition are also included.

(2)Comprised primarily of accruals related to commercial and government rebates as well as returns. The accrued revenue reserve at December 31, 2020 is higher than prior year primarily due to higher rebates largely driven by government sponsored programs.

(3)Comprised primarily of accruals related to interest payable as well as other business-related expenses.